A Sham Controlled Study of the Effects of Ultrasonic Shockwaves as a Treatment for Chronic Pelvic Pain

Chronic Pelvic Pain Clinical Trial

— CPPESWT  

Official title:

Low Intensity Extracorporeal Shockwave Therapy Against Chronic Pelvic Pain: a Randomized and Sham Controled Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02042651
• Other study ID #: H-3-2013-178
• Secondary ID: HEH-2013-33
• Status: Withdrawn
• Phase: N/A
• First received: January 10, 2014
• Last updated: March 23, 2015
• Start date: February 2014
• Est. completion date: February 2016

Study information

• Verified date: March 2015
• Source: Herlev Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Danish Dataprotection Agency
• Study type: Interventional

Clinical Trial Summary

Introduction:

Chronic pelvic pain with unknown pathology is a condition that affects both men and women. the condition is defined as pelvic pain lasting for a minimum of 6 months without any known etiology eg. cancer, infection or inherent anatomical abnormalities. Low intensity extracorporeal shockwave therapy (LIESWT) enables the practitioner to deliver a small amount of energy approximately 5 cm under the skin of the patient without damaging the skin. This have been shown to increase blood flow and accelerate healing which could also be beneficial in chronic pelvic pain patients.The purpose of this study is to investigate the effects of LIESWT on chronic pelvic pain.

Methods:

All patients will be treated at the Birthe Bonde clinic, in Copenhagen, Denmark.

The investigators anticipate to include 100 chronic pelvic pain patients in the study.

included patients will be randomized into two groups: active treatment or sham treatment.

All patients will be required to provide a urine sample and a semen sample prior to final inclusion. Samples will be analyzed for microbial growth. Furthermore, patients will undergo a digital rectal exploration and finally all patients is required to provide an informed consent in order to be included in the study.

A Storz Doulith SD1 T-Top (CE1275) will be used to generate shockwaves. Patients will receive the treatment once a week until their symptoms have seized or for a maximum of 6 times. Each treatment consists of 3000 shockwaves applied to the perineum with a energy density of 0.25-0.40 millijoule(mJ)/mm2 and a frequency of 3 hz.

Participants will fill out a questionnaire one week before the treatment, one week, four weeks, and twelve weeks after the last treatment.

Possible gains from this study:

The investigators hope to provide further evidence for this treatment and consequently be able to offer the treatment as an alternative to the very limited array of treatments existing for this group of patients today.

Ethics, funding, and publication:

The study is performed in compliance with the Helsinki declaration. External funding have been applied for but not yet received. Participants will be informed of sources of external funding. The result of the study will be published as soon as possible, preferably in a peer-reviewed international journal.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• pelvic pain with a duration of more than 6 months

• be able to read and understand the study information

Exclusion Criteria:

• known etiology for pelvic pain eg. cancer, infection, inherent abnormalities.

• diagnosed with hemophilia

• receiving anti thrombotic therapy other than hearth magnyl

• diagnosed with thrombocytosis

• active cancer

• treated with IV glucocorticoids within the last 6 months

• disease in the rectal area

• abnormal digital rectal exploration

• bacteriospermia

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Pelvic Pain
• Pelvic Pain

Intervention

Device:
• Low intensity extracorporeal shockwave therapy
Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session
• Sham low intensity extracorporeal shockwave therapy
Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.

Locations

Country	Name	City	State
Denmark	Birthe bonde klinikken	Copenhagen E	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Herlev Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in NIH-Chronic Prostatitis Symptom Index	A questionnaire designed to provide symptom scores for patients with chronic prostatitis. The index provides scores on pain, urinary symptoms, and quality of life.	Change from baseline to twelve weeks after final treatment	No
Secondary	Change in The International Index of Erectile Function 5	Questionnaire designed to evaluate erectile capabilities. The questionnaire provides a score between 5 and 25.	Change from baseline to twelve weeks after final treatment	No
Secondary	Change in The International prostate symptom score	A questionnaire designed to provide information on lower urinary tract symptoms and their impact on quality of life. scores range from 0 to 35.	Change from baseline to twelve weeks after final treatment	No
Secondary	Global satisfaction score	One question designed to estimate treatment satisfaction on a four point Likert scale.	Twelve weeks after final treatment	No